CNV1014802 hydrochloride

Research use only, not for human use.

CNV1014802 (GSK-1014802, Raxatrigine, Vixotrigine) is a potent, selective Nav1.7 sodium channel blocker.

CNV1014802 (GSK-1014802, Raxatrigine, Vixotrigine) is a potent, selective Nav1.7 sodium channel blocker, shows analgesic effects and potential in the treatment of cognitive symptoms of schizophrenia in vivo.Pain Phase 2 Clinical.

Like lamotrigine, both GSK2 and GSK3 were able to prevent the deficit in reversal learning produced by PCP, thus confirming their potential in the treatment of cognitive symptoms of schizophrenia. However, higher doses than those required for anticonvulsant efficacy of the drugs were needed for activity in the reversal-learning model, suggesting a lower therapeutic window relative to mechanism-dependent central side effects for this indication. Raxatrigine (GSK-1014802) received orphan-drug designation from the US Food and Drug Administration in July 2013.

——

GSK-1014802 hydrochloride | CNV-1014802 hydrochloride | Raxatrigine hydrochloride | Vixotrigine

Membrane Transporter/Ion Channel

Sodium Channel

Sodium Channel

Neurological Disease

Pain

934240-31-0

350.815

C18H20ClFN2O2

>98% (HPLC)

DMSO: ≥ 31 mg/mL

C1CC(NC1C2=CC=C(C=C2)OCC3=CC=CC=C3F)C(=O)N.Cl

2-Pyrrolidinecarboxamide, 5-[4-[(2-fluorophenyl)methoxy]phenyl]-, hydrochloride (1:1), (2S,5R)-

(-20℃)

With Ice Pack

≥ 2 years